Vinay Prasad

Vinay Prasad is departing from the United States===Food and Drug Administration (FDA) for the second time in less than a year, following controversial decisions regarding vaccine and specialty drug reviews. His departure creates uncertainty for pharmaceutical and biotechnology companies awaiting FDA approvals.

Vinay Prasad, the controversial head of the U.S. Food and Drug Administration's vaccines and biologics unit, is leaving the agency. His departure has been met with positive market reactions for companies whose drug approvals he had previously challenged.

Vinay Prasad, a top deputy at the United States===Food and Drug Administration, co-authored the The New England Journal of Medicine piece announcing the shift in drug approval standards. While supporting the single-trial default, he has also shown a more restrictive approach to other products like vaccines and gene therapies, causing some market uncertainty.

Dr. Vinay Prasad, director of the United States===Food and Drug Administration's Center for Biologics Evaluation and Research, signed the refusal-to-file letter to Moderna. He has been a critic of COVID-19 vaccines and has indicated changes to the vaccine approval process, aligning with Robert F. Kennedy Jr.'s stance.

Dr. Vinay Prasad, leading the United States===Food and Drug Administration's Center for Biologics Evaluation and Research, is implicated in the initial rejection of Moderna's flu shot, with critics suggesting his actions are ideologically driven.